|
Basic Characteristics of Mutations
|
|
Mutation Site
|
A146V |
|
Mutation Site Sentence
|
Furthermore, an additional ongoing substitution (A146V) was identified in the NS4A gene of P20-2 strain, while another substitution (G196V) was found in the NS1 gene of P20-3 strain (marked in blue font in Table 1). |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
NS4A |
|
Standardized Encoding Gene
|
NS4A
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
JN628279;AY640589
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
39398246
|
|
Title
|
A safer cell-based yellow fever live attenuated vaccine protects mice against YFV infection
|
|
Author
|
Guo W,Jiang T,Rao J,Zhang Z,Zhang X,Su J,Yin C,Lu M,Hu X,Shan C
|
|
Journal
|
iScience
|
|
Journal Info
|
2024 Sep 17;27(10):110972
|
|
Abstract
|
The live attenuated yellow fever vaccine (YF17D) has caused controversial safety issues in history with low-yield problems, which has led to a large population being unable to be vaccinated and vaccine shortage in facing recent outbreaks. Here, we report a safer live attenuated vaccine candidate, YF17D-Delta77, which contains 77 nucleotides deletion in the 3' untranslated region (3' UTR) of the YF17D genome. YF17D-Delta77 exhibited no neurotropism and decreased viscerotropism and caused significantly lower lethality in mice compared to YF17D. Mechanistically, the deletion enhanced the sensitivity of the virus to type I and type II interferon responses, which hindered viral replication. Encouragingly, YF17D-Delta77 provided comparable immune protection in mice as did YF17D. Even 10 PFU of YF17D-Delta77 completely protected mice against YFV-Asibi challenge. In addition, the Delta77 mutation showed excellent stability after successive passages in Vero cells. Collectively, the data suggest that further development of YF17D-Delta77 as vaccine candidate is warranted.
|
|
Sequence Data
|
-
|
|
|